MedPath

Aztreonam

Generic Name
Aztreonam
Brand Names
Azactam, Cayston
Drug Type
Small Molecule
Chemical Formula
C13H17N5O8S2
CAS Number
78110-38-0
Unique Ingredient Identifier
G2B4VE5GH8
Background

A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.

Indication

For the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract infections, lower respiratory tract infections, septicemia, skin and skin-structure infections, intra-abdominal infections, and gynecologic infections.

Associated Conditions
Bone and Joint Infections, Cystic Fibrosis (CF), Febrile Neutropenia, Gynecological Infection, Intraabdominal Infections, Lower Respiratory Tract Infection (LRTI), Osteomyelitis, Septic Arthritis, Septicemia, Skin Infections, Urinary Tract Infection, Uncomplicated Gonorrhea
Associated Therapies
-
Clinical Trials
Related News

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

Phase 1
Recruiting
Conditions
Advanced Non Small Cell Lung Cancer
Interventions
Drug: aerosolized aztreonam
Drug: aerosolized vancomycin
Drug: pembrolizumab
First Posted Date
2023-03-21
Last Posted Date
2024-12-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
20
Registration Number
NCT05777603
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam

Phase 1
Completed
Conditions
Bacterial Infection
Interventions
Drug: Ceftazidime-Avibactam
Drug: AZACTAM
First Posted Date
2019-06-06
Last Posted Date
2022-06-07
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
48
Registration Number
NCT03978091
Locations
🇺🇸

Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit, Durham, North Carolina, United States

Aztreonam for Pharyngeal Gonorrhea

Phase 2
Completed
Conditions
Gonorrhea of Pharynx
Gonorrhea
Interventions
Drug: Aztreonam
First Posted Date
2019-03-08
Last Posted Date
2022-01-18
Lead Sponsor
University of Washington
Target Recruit Count
32
Registration Number
NCT03867734
Locations
🇺🇸

Public Health -- Seattle & King County STD Clinic, Seattle, Washington, United States

Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: SPR741
Drug: Piperacillin/tazobactam
Drug: Ceftazidime
Drug: Aztreonam
First Posted Date
2017-12-18
Last Posted Date
2018-01-05
Lead Sponsor
Spero Therapeutics
Target Recruit Count
27
Registration Number
NCT03376529
Locations
🇬🇧

Simbec Research, Ltd., Merthyr Tydfil,, Mid Glamorgan, United Kingdom

Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis

Phase 4
Completed
Conditions
Infection
Cystic Fibrosis
Pseudomonas
Interventions
Drug: Aztreonam
Drug: Standard Care
First Posted Date
2016-09-09
Last Posted Date
2019-10-07
Lead Sponsor
Liverpool Heart and Chest Hospital NHS Foundation Trust
Target Recruit Count
16
Registration Number
NCT02894684
Locations
🇬🇧

Liverpool Heart & Chest Hospital NHS Trust, Liverpool, United Kingdom

Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)

Phase 3
Completed
Conditions
Skin Diseases, Infectious
Skin Diseases, Bacterial
Interventions
Drug: Tedizolid Phophate
Drug: Antibiotic comparator
Drug: Aztreonam
Drug: Metronidazole
First Posted Date
2014-10-28
Last Posted Date
2019-08-07
Lead Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Target Recruit Count
120
Registration Number
NCT02276482

Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections.

Phase 3
Terminated
Conditions
Complicated Skin and Soft Tissue Infection
Interventions
Drug: Ceftaroline fosamil
Drug: Vancomycin
Drug: Aztreonam
First Posted Date
2014-07-28
Last Posted Date
2017-09-06
Lead Sponsor
Pfizer
Target Recruit Count
4
Registration Number
NCT02202135
Locations
🇹🇷

Research site, Izmir, Turkey

Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Phase 3
Completed
Conditions
Skin Structures and Soft Tissue Infections
Skin and Subcutaneous Tissue Bacterial Infections
Interventions
Drug: vancomycin
Drug: delafloxacin
Drug: aztreonam
First Posted Date
2013-11-15
Last Posted Date
2017-11-17
Lead Sponsor
Melinta Therapeutics, Inc.
Target Recruit Count
850
Registration Number
NCT01984684
Locations
🇨🇳

Melinta 303 Study Site, Zhonghe, Taiwan

Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Phase 3
Completed
Conditions
Skin and Subcutaneous Tissue Bacterial Infections
Interventions
Drug: Delafloxacin
Drug: Vancomycin
Drug: Aztreonam
Drug: Placebo
First Posted Date
2013-03-15
Last Posted Date
2017-09-27
Lead Sponsor
Melinta Therapeutics, Inc.
Target Recruit Count
660
Registration Number
NCT01811732
Locations
🇺🇦

Melinta Investigational Site, Zaporizhzhia, Ukraine

Antibiotic Prophylaxis for Transrectal Prostate Biopsy

Phase 4
Completed
Conditions
Infection
Interventions
Drug: trimethoprim-sulfamethoxazole
Drug: Ciprofloxacin
Drug: cefuroxime
Drug: ceftriaxone
Drug: gentamicin
Drug: amikacin
Drug: aztreonam
Drug: imipenem
First Posted Date
2012-08-08
Last Posted Date
2019-06-25
Lead Sponsor
Northwestern University
Target Recruit Count
563
Registration Number
NCT01659866
Locations
🇺🇸

Northwestern University Department of Urology, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy